Methylbenzethonium Chloride Topical Powder
Methylbenzethonium Chloride Topical Powder contains NLT 85.0% and NMT 115.0% of the labeled amount of methylbenzethonium chloride (C28H44ClNO2·H2O) in a suitable fine powder base, free from grittiness.
Sample: Suspend 0.1 g of methylbenzethonium chloride topical powder in 10 mL of water.
Analysis: Add 0.1 g of sodium carbonate, 1 mL of bromophenol blue TS, and 10 mL of chloroform to the Sample, and shake the mixture.
Acceptance criteria: The chloroform layer is blue.
Standard stock solution: 4.446 mg/mL of USP Docusate Sodium RS in isopropyl alcohol (equivalent to 0.01 M of USP Docusate Sodium RS). Store this solution in a tightly-stoppered glass container. Prepare the Standard solution on the day of use.
Standard solution: 44.46 µg/mL of USP Docusate Sodium RS in water from the Standard stock solution (equivalent to 0.1 mM of USP Docusate Sodium RS)
Sample solution: Transfer an amount of Topical Powder, equivalent to 0.5 mg of methylbenzethonium chloride, to a glass-stoppered, 50-mL cylinder. Add 5 mL of chloroform (freshly purified by shaking 100 mL with 10 g of silica gel, allowing to settle, and withdrawing the supernatant), 5 mL of phosphoric acid solution (1 in 10), and 1 mL of 0.05 mg/mL of safranin O solution.
Analysis: Titrate the Sample solution with the Standard solution until 1 mL from the endpoint, then shake the stoppered tube vigorously for about 2 min, and continue the titration in 0.1-mL increments, shaking vigorously after each addition, until a pink color appears in the chloroform layer. Perform a blank determination, and make any necessary correction (see Titrimetry 541). Each mL of Standard solution is equivalent to 48.01 µg of methylbenzethonium chloride (C28H44ClNO2·H2O).
Acceptance criteria: 85.0%115.0%
• pH 791: 9.010.5, in a dispersion of 10 mg/mL of the sample in carbon dioxide-free water
• Powder Fineness 811: NLT 99% of it passes through a No. 200 sieve.
• Packaging and Storage: Preserve in well-closed containers.
• USP Reference Standards 11
Auxiliary Information Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 3867Pharmacopeial Forum: Volume No. 30(2) Page 516